한빛사
>
한빛사논문
한빛사논문
6
- 조회908
Clin. Mol. Hepatol., Feb 06 2025, | https://doi.org/10.3350/cmh.2024.1038
GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma
Hyung Seok Kim1, Jung Hwan Yoon2, Ji Yi Choi3,4, Moon Gyeong Yoon3, Geum Ok Baek3, Minji Kang3,4, Se Ha Jang3,4, Won Park5, Yunjin Go4,6, Jestlin Tianthing Ng4,6, Suk Woo Nam2, Jee-Yeong Jeong1, Ji Eun Han3, Hyo Jung Cho3, Su Bin Lim6, Soon Sun Kim3, Jae Youn Cheong3, Jung Woo Eun3
1Department of Biochemistry, College of Medicine, Kosin University; Seo-gu, Busan 49267, South Korea
2Department of Pathology, College of Medicine, The Catholic University of Korea; Seocho-gu, Seoul 06591, South Korea
3Department of Gastroenterology, Ajou University School of Medicine; 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, South Korea
4Department of Biomedical Sciences, Ajou University Graduate School of Medicine; 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, South Korea
5Department of Bioscience and Biotechnology, Graduate School, Chungnam National University; 99 Daehak-ro, Yuseong-gu, Daejeon 34134, South Korea
6Department of Biochemistry and Molecular Biology, Ajou University School of Medicine; 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, South Korea
*Hyung Seok Kim and Jung Hwan Yoon contributed equally to this work.
Correspondence : Jung Woo Eun
1Department of Biochemistry, College of Medicine, Kosin University; Seo-gu, Busan 49267, South Korea
2Department of Pathology, College of Medicine, The Catholic University of Korea; Seocho-gu, Seoul 06591, South Korea
3Department of Gastroenterology, Ajou University School of Medicine; 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, South Korea
4Department of Biomedical Sciences, Ajou University Graduate School of Medicine; 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, South Korea
5Department of Bioscience and Biotechnology, Graduate School, Chungnam National University; 99 Daehak-ro, Yuseong-gu, Daejeon 34134, South Korea
6Department of Biochemistry and Molecular Biology, Ajou University School of Medicine; 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, South Korea
*Hyung Seok Kim and Jung Hwan Yoon contributed equally to this work.
Correspondence : Jung Woo Eun
Abstract
Backgrounds/Aims
Hepatocellular carcinoma (HCC) is characterized by high recurrence and mortality, necessitating the identification of reliable biomarkers. In this study, we aimed to identify the predictive gene signatures for HCC recurrence and evaluate the efficiency of GULP PTB domain-containing engulfment adaptor 1 (GULP1) as a predictive and diagnostic marker and therapeutic target for HCC.
Methods
We analyzed genomic datasets from The Cancer Genome Atlas and Gene Expression Omnibus databases via least absolute shrinkage and selection operator Cox regression and 10-fold cross-validation, leading to the development of a 15-gene risk score model, which was validated using three independent datasets. Serum GULP1 and α-fetoprotein levels were assessed to determine the diagnostic accuracy of the model. Using clinical cohorts and patient sera, GULP1 roles were examined, and functional assays in vitro and in vivo were used to evaluate its effects on cell growth, epithelial–mesenchymal transition (EMT), ADP-ribosylation factor 6 activation, and β-catenin signaling.
Results
Our newly developed risk-score model accurately predicted recurrent HCC in all datasets. Among the 15 genes in the risk score model, GULP1 was overexpressed in patients with HCC and independently predicted HCC recurrence. Its expression modulation influenced cell growth and EMT, with observed effects on ADP-ribosylation factor 6 activation and β-catenin signaling pathways.
Conclusions
GULP1 is a crucial biomarker for HCC, serving as a non-invasive diagnostic and predictive tool. It also plays key roles in HCC progression. Our findings highlight the potential use of GULP1 in treatment strategies targeting EMT and HCC recurrence to improve the personalized care and patient outcomes.
Hepatocellular carcinoma (HCC) is characterized by high recurrence and mortality, necessitating the identification of reliable biomarkers. In this study, we aimed to identify the predictive gene signatures for HCC recurrence and evaluate the efficiency of GULP PTB domain-containing engulfment adaptor 1 (GULP1) as a predictive and diagnostic marker and therapeutic target for HCC.
Methods
We analyzed genomic datasets from The Cancer Genome Atlas and Gene Expression Omnibus databases via least absolute shrinkage and selection operator Cox regression and 10-fold cross-validation, leading to the development of a 15-gene risk score model, which was validated using three independent datasets. Serum GULP1 and α-fetoprotein levels were assessed to determine the diagnostic accuracy of the model. Using clinical cohorts and patient sera, GULP1 roles were examined, and functional assays in vitro and in vivo were used to evaluate its effects on cell growth, epithelial–mesenchymal transition (EMT), ADP-ribosylation factor 6 activation, and β-catenin signaling.
Results
Our newly developed risk-score model accurately predicted recurrent HCC in all datasets. Among the 15 genes in the risk score model, GULP1 was overexpressed in patients with HCC and independently predicted HCC recurrence. Its expression modulation influenced cell growth and EMT, with observed effects on ADP-ribosylation factor 6 activation and β-catenin signaling pathways.
Conclusions
GULP1 is a crucial biomarker for HCC, serving as a non-invasive diagnostic and predictive tool. It also plays key roles in HCC progression. Our findings highlight the potential use of GULP1 in treatment strategies targeting EMT and HCC recurrence to improve the personalized care and patient outcomes.
논문정보
- Research article
- 2025년 02월 (BRIC 등록일 2025-02-07)
- 국내 연구진
- 의약학 > 종양의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
